Friend's E-mail:
 (maximum of 3 addresses separated by commas)
Your E-mail:
A Brief Comment (150 char max / 25 word max)
Article:

ImaRx changes courses,
back to microbubbles

In a second change of directions this year, ImaRx Therapeutics May 7 announced it has agreed to sell its inventory of the anti-clotting drug urokinase for $17 million cash to Microbix in Toronto, Canada.

Security image: (Case sensitive)
   

Note: the e-mail sent will contain information, such as your IP address (38.107.191.110), for purposes of tracking abuse. Use of this software to spam or harass individuals can and may result in penalties punishable by law.